Actoplus Met is owned by Takeda Pharms Usa.
Actoplus Met contains Metformin Hydrochloride; Pioglitazone Hydrochloride.
Actoplus Met has a total of 2 drug patents out of which 0 drug patents have expired.
Actoplus Met was authorised for market use on 29 August, 2005.
Actoplus Met is available in tablet;oral dosage forms.
The generics of Actoplus Met are possible to be released after 03 February, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9101660||TAKEDA PHARMS USA||Solid preparation|| |
(3 years from now)
|US9320714||TAKEDA PHARMS USA||Tablet|| |
(5 years from now)
Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 August, 2005
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic